Reaction Details Report a problem with these data
Target
Nuclear receptor coactivator 2 [740-753]
Ligand
BDBM50030474
Substrate
n/a
Meas. Tech.
Competitive Binding Assay
IC50
125±n/a nM
Citation
 Tanis, SP; Larsen, SD; Artman, III, GD; Parker, T PPAR-sparing compounds for the treatment of metabolic diseases US Patent  US9562012 Publication Date 2/7/2017 
Target
Name:
Nuclear receptor coactivator 2 [740-753]
Synonyms:
BHLHE75 | Human nuclear receptor coactivator 2 (aa 740-753) | NCOA2 | NCOA2_HUMAN | Nuclear receptor coactivator 2 (aa 740-753) | SRC2 | SRC2-3 peptide | TIF2
Type:
fluorescent labeled peptide
Mol. Mass.:
1704.90
Organism:
n/a
Description:
Q15596 aa 740-753
Residue:
14
Sequence:
KENALLRYLLDKDD
 
Inhibitor
Name:
BDBM50030474
Synonyms:
Avandamet | Avandaryl | Avandia | BRL-49653 | CHEBI:50122 | Rosiglitazone | US10744117, Compound Rosiglitazone | US9562012, rosiglitazone
Type:
Small organic molecule
Emp. Form.:
C18H19N3O3S
Mol. Mass.:
357.427
SMILES:
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
Structure:
Search PDB for entries with ligand similarity: